Loading...
•
Jun 30, 2021
Personalis Q2 2021 Earnings Report
Reported record revenue and achieved twentieth consecutive quarter of growth.
Key Takeaways
Personalis, Inc. reported record quarterly revenue of $21.7 million, an 11% increase compared to the second quarter of 2020. Revenue from biopharma and all other customers grew 72% over the same period of the prior year.
Record quarterly revenue of $21.7 million, an 11% increase year-over-year.
Revenue from biopharma and all other customers, excluding VA MVP, increased 72% year-over-year.
Achieved milestone of delivering more than 125,000 whole human genome sequences to the VA MVP.
NeXT Personal, Personalis' Minimal Residual Disease (MRD) offering, remains on-track for launch in 2021.
Forward Guidance
Personalis expects total revenue for Q3 2021 to be approximately $22.2 million and a net loss in the range of $17 million to $18 million. For the full year of 2021, Personalis expects total revenue to be approximately $85 million and a net loss in the range of $65 million to $70 million.
Positive Outlook
- Total revenue to be approximately $22.2 million for Q3 2021
- Revenue from biopharma and all other customers, excluding VA MVP, to be in the range of $7.5 million to $8.5 million for Q3 2021
- Total revenue to be approximately $85 million for the full year of 2021
- Revenue from biopharma and all other customers, excluding VA MVP, to be in the range of $33 million to $34 million for the full year of 2021
- Estimated outstanding shares of 44 million
Challenges Ahead
- Net Loss to be in the range of $17 million to $18 million for Q3 2021
- Net Loss to be in the range of $65 million to $70 million for the full year of 2021
- Timing and pace of new orders from customers, including from the U.S. Department of Veterans Affairs Million Veteran Program
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...